OTCMKTS:ASPCF Acerus Pharmaceuticals (ASPCF) Stock Price, News & Analysis $0.22 0.00 (0.00%) As of 07/21/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Acerus Pharmaceuticals Stock (OTCMKTS:ASPCF) Get Acerus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.22▼$0.2250-Day Range$0.22▼$0.2252-Week Range$0.22▼$8.16VolumeN/AAverage Volume1,500 shsMarket Capitalization$1.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the development, commercialization and marketing of prescription therapies addressing women’s health and related endocrine conditions. Headquartered in Mississauga, Ontario, with commercial operations in Princeton, New Jersey, the company leverages licensing and co-promotion agreements to bring novel hormone therapies to market. The company’s commercial portfolio includes CombiPatch, a combined estradiol/testosterone transdermal system indicated for hormone replacement therapy in post-menopausal women, and IMVEXXY, a low-dose estradiol vaginal insert for the treatment of dyspareunia associated with menopausal vulvar and vaginal atrophy. Both products are marketed under license from Endoceutics, Inc., and are sold in the United States and Canada through Acerus’s dedicated sales teams and strategic partners. Beyond its marketed products, Acerus maintains a clinical development pipeline aimed at unmet needs in women’s sexual health and men’s hypogonadism. Lead programs include an injectable testosterone therapy for female sexual dysfunction and a transdermal gel formulation targeting male testosterone deficiency. The company also explores new delivery technologies and formulations to enhance the safety and convenience of hormone therapies. Acerus is led by President and Chief Executive Officer Jonathan G. Barrett, whose background in pharmaceutical strategy and business development supports the company’s growth initiatives. Through its North American footprint and collaborative agreements, Acerus seeks to expand patient access to specialized endocrine treatments.AI Generated. May Contain Errors. Read More Receive ASPCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASPCF Stock News HeadlinesAcerus Announces Commencement of Court-Approved Sale and Investment Solicitation ProcessMarch 14, 2023 | finance.yahoo.comAcerus Pharmaceuticals: Top 10 Undervalued Nano Cap Stocks on TSX (ASP)January 16, 2023 | theglobeandmail.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker. | Behind the Markets (Ad)Acerus Reports Third Quarter 2022 Financial ResultsNovember 15, 2022 | finance.yahoo.comAcerus Announces Amendment to Promissory Note Due to Former Serenity ShareholdersOctober 3, 2022 | finance.yahoo.comAcerus Pharmaceuticals to Initiate Strategic Review of OperationsSeptember 21, 2022 | marketwatch.comAcerus Announces Initiation of Strategic ReviewSeptember 21, 2022 | finance.yahoo.comAcerus Pharmaceuticals CFO resigns effective November 20, 2022August 23, 2022 | seekingalpha.comSee More Headlines ASPCF Stock Analysis - Frequently Asked Questions How have ASPCF shares performed this year? Acerus Pharmaceuticals' stock was trading at $0.22 at the beginning of the year. Since then, ASPCF shares have increased by 0.0% and is now trading at $0.22. When did Acerus Pharmaceuticals' stock split? Shares of Acerus Pharmaceuticals reverse split on the morning of Friday, April 29th 2022.The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Acerus Pharmaceuticals? Shares of ASPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/22/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ASPCF CIKN/A Webwww.aceruspharma.com Phone(416) 679-0771Fax905-569-1809Employees14Year Founded2008Profitability EPS (Trailing Twelve Months)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.82 million Net Margins-924.33% Pretax Margin-924.33% Return on EquityN/A Return on Assets-74.62% Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick Ratio0.34 Sales & Book Value Annual Sales$2.12 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($3.38) per share Price / Book-0.07Miscellaneous Outstanding Shares7,708,000Free FloatN/AMarket Cap$1.70 million OptionableNot Optionable Beta0.69 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:ASPCF) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acerus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
